Search EN menu en EIB GROUP CLIENT PORTAL
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Summary sheet

    Release date
    2 October 2020
    Status
    Reference
    Approved | 11/11/2020
    20200584
    Project name
    Promoter - financial intermediary
    COVID-19 ESSENTIAL API MANUFACTURING IN AFRICA
    COUNTERPART(S) TO BE DETERMINED
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 50 million
    EUR 100 million
    Location
    Sector(s)
    • Health - Human health and social work activities
    Description
    Objectives

    The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa (SSA).

    The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa. The ultimate objective is to improve the availability of pharmaceutical products in the region and to increase the robustness of the pharmaceutical supply chain by reducing dependency on imports.

    Environmental aspects
    Procurement

    The overall environmental impact and the residual environmental risks of the operation are unknown at this stage and will be assessed at the appraisal of individual sub-operations. The Bank will require the beneficiaries to ensure that implementation of the sub-projects will be done in accordance with the Bank's environmental and social policy and standards.

    The Bank will require that the beneficiaries ensure that the implementation of the sub-operations will be done in accordance with the Bank's Guide to Procurement.

    Related projects
    Related sub-project
    Related sub-project

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - COVID-19 ESSENTIAL API MANUFACTURING IN AFRICA
    Publication Date
    26 Nov 2020
    Document language
    Main Topic
    Lending
    Document Number
    133740236
    Document Focus
    Environmental Information
    Project Number
    20200584
    Sector(s)
    Countries
    Publicly available
    Download now
    Environmental and Social Data Sheet (ESDS) - RWANDA VACCINE MANUFACTURING
    Publication Date
    31 Jan 2024
    Document language
    Main Topic
    Lending
    Document Number
    163212926
    Document Focus
    Environmental Information
    Project Number
    20200584
    Sector(s)
    Countries
    Publicly available
    Download now
    Other links

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

    Related publications